<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04532229</url>
  </required_header>
  <id_info>
    <org_study_id>BPL-Nim-DIPG-1</org_study_id>
    <nct_id>NCT04532229</nct_id>
  </id_info>
  <brief_title>Nimotuzumab in Combined With Concurrent Radiochemotherapy in the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Children</brief_title>
  <official_title>A Multicenter, Prospective, Open and Single Arm Clinical Study of Nimotuzumab Combined With Concurrent Radiochemotherapy in the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotech Pharmaceutical Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotech Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, single arm, multicenter clinical study. The purpose of the&#xD;
      study is to evaluate the clinical efficacy and safety of combination Nimotuzumab with&#xD;
      concurrent radiochemotherapy in children with newly diagnosed diffuse intrinsic pontine&#xD;
      glioma(DIPG).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical study is designed as a prospective, open-label, single arm, multicenter study&#xD;
      to evaluate the clinical efficacy and safety of combination Nimotuzumab with concurrent&#xD;
      radiochemotherapy in children with newly diagnosed diffuse intrinsic pontine glioma(DIPG).&#xD;
      The main endpoint is objective response rate, 1-year overall survival rate is also observed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2021</start_date>
  <completion_date type="Anticipated">December 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 8, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate #ORR#</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Proportion of patients with partial or complete response in tumor burden as defined by RECIST.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-year overall survival</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The possibility that a patient who has lived for 1 year after treatment will still survive. OS is defined as the time from enrollment to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival#PFS#</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 30 days after last administration of Nimotuzumab</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Diffuse Intrinsic Pontine Glioma</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nimotuzumab+CRT(concurrent IMRT and TMZ)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimotuzumab+CRT(concurrent IMRT and TMZ)</intervention_name>
    <description>Drug: Nimotuzumab Concurrent radiochemotherapy period, 150mg/m2, weekly, for 6 weeks; Maintenance period, from the 7th to the 52nd week, 150mg/m2, every two weeks until disease progression or intolerable toxicity.&#xD;
Other Names: h-R3&#xD;
Drug: Temozolomide Concurrent radiochemotherapy period, 75mg/m2, daily, for 6 weeks; Maintenance period, rest from the 7th to 10th weeks, from the 11th week, 150-200mg/m2, day1 to day5, 21 days for a cycle, for 6 cycles.&#xD;
Other Names: TMZ</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary and sign a consent form;&#xD;
&#xD;
          2. Age 3-15 years old, gender unlimited;&#xD;
&#xD;
          3. Histology or imaging diagnosed as diffuse intrinsic pontine glioma, patients haven't&#xD;
             received any anti-tumor treatment;&#xD;
&#xD;
          4. According to the RANO criteria, at least one measurable lesion;&#xD;
&#xD;
          5. Before enrollment, the results of laboratory examination are in accordance with:&#xD;
&#xD;
             Blood routine test: platelet count ≥ 100 × 10^9/L; absolute neutrophil count ≥ 1.5 ×&#xD;
             10^9/L or leukocyte count ≥ 3.0 × 10^9/L; hemoglobin ≥ 90g/L; Blood biochemistry:&#xD;
             aspartate aminotransferase#AST# ≤ 3 ×Upper Limit Of Normal#ULN#; alanine&#xD;
             aminotransferase#ALT# ≤ 3 × ULN; total bilirubin ≤ 1.5 × ULN; serum creatinine ≤ 1.5 ×&#xD;
             ULN;&#xD;
&#xD;
          6. Lansky score ≥ 60;&#xD;
&#xD;
          7. Expected survival time ≥ 3 months;&#xD;
&#xD;
          8. Fertile subjects are willing to take contraceptive measures during the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recurrent DIPG;&#xD;
&#xD;
          2. Have received any other anti-tumor treatment for DIPG, including surgical treatment&#xD;
             (except biopsy), chemotherapy, radiotherapy, targeted drugs, immunotherapy, etc;&#xD;
&#xD;
          3. Uncontrollable infection, epilepsy and / or hypertension and / or hyperglycemia;&#xD;
&#xD;
          4. Human immunodeficiency virus #HIV# infection or active hepatitis B infection or&#xD;
             hepatitis C infection;&#xD;
&#xD;
          5. Active hemorrhage found by CT or MRI before inclusion and / or inability to carry out&#xD;
             CT and MRI examination;&#xD;
&#xD;
          6. Major operation (except biopsy) were performed within four weeks before inclusion;&#xD;
&#xD;
          7. Decompensated heart failure (NYHA grades III and IV), unstable angina, acute&#xD;
             myocardial infarction, persistent and clinically significant arrhythmia within three&#xD;
             months of inclusion;&#xD;
&#xD;
          8. Have other malignant tumor history;&#xD;
&#xD;
          9. Known allergy to Nimotuzumab, temozolomide or its analogues or any component of the&#xD;
             prescription;&#xD;
&#xD;
         10. Unable to tolerate radiotherapy;&#xD;
&#xD;
         11. Other reasons that are not suitable to participate in this study according to the&#xD;
             researcher's judgment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaojun Yuan</last_name>
    <role>Study Chair</role>
    <affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaoguang Qiu</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaojun Yuan</last_name>
    <phone>13817266192</phone>
    <email>13651718916@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaoguang Qiu</last_name>
    <phone>13701009917</phone>
    <email>ttyy6611@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Third People's Hospital of Zhengzhou</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gang Wang</last_name>
      <phone>18037791710</phone>
      <email>z214023wanggang@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital of Centre-south University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liangfang Shen</last_name>
      <phone>13975805137</phone>
      <email>slf1688@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qing Mao</last_name>
      <phone>18980601506</phone>
      <email>qingmao2000@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoguang Qiu</last_name>
      <phone>13701009917</phone>
      <email>ttyy6611@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wenbin Ma</last_name>
      <phone>13701364566</phone>
      <email>MAWB2001@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xuanwu Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingtang Lin</last_name>
      <phone>15801588169</phone>
      <email>kingsang2002@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rongjie Tao</last_name>
      <phone>13969191909</phone>
      <email>053113969191909@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaojun Yuan</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nimotuzumab</keyword>
  <keyword>Temozolomide</keyword>
  <keyword>DIPG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Diffuse Intrinsic Pontine Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimotuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

